<DOC>
	<DOCNO>NCT01065454</DOCNO>
	<brief_summary>The aim study ass whether increase oral dos Riociguat safe improve well-being , symptom outcome patient pulmonary hypertension associate leave ventricular systolic dysfunction</brief_summary>
	<brief_title>A Study Test Effects Riociguat Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction</brief_title>
	<detailed_description>Pharmacokinetics parameter regard exploratory parameter . Adverse event data cover Adverse event section .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<criteria>Male female patient symptomatic pulmonary hypertension due leave ventricular systolic dysfunction despite optimized heart failure therapy Types pulmonary hypertension group 2.1 Dana Point Classification</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>Left ventricular dysfunction</keyword>
</DOC>